Lifecare’s partner Digital Diagnostics AG seeks additional approval in Germanyfor corona virus rapid test – plan for scaling capacities with productionpartners in USA and Europe and aim to bring test to the market in millions. The Norwegian listed company Lifecare AS (LIFE-ME) has a 25% ownership inDigital Diagnostics AG which has developed an accurate and reliable rapid testable to detect corona virus from the time of infection, contrary to other testson the market that can only detect the antibodies 5-7 days after the infection.The test is independent of lab analysis, providing test result within minutes atthe point-of-care. Digital Diagnostics announced June 12th, 2020, that the company has applied tothe German Federal Institute for Drugs and Medical Devices (BfArM) for approvalof the Digid CantisenseTM SARS-CoV-2 test for Germany. This application comes inaddition to the previous application to the US FDA, announced June 2de, 2020. Digital Diagnostics expect approval from BfArM and FDA in the next few weeks,where after the goal is to bring the tests to the market in millions. In theshort-term Digital Diagnostics are further scaling its capasities withproduction partners in the USA and Europe. https://app.handelsblatt.com/technik/forschung-medizin/pandemie-corona-nachweis-in-fuenf-minuten-neue-generation-von-schnelltests-draengt-auf-den-markt/25905060.html?ticket=ST-3806779-6C6zKjUKJhghdkEmaDdF-ap3For additional background information, we refer to: https://newsweb.oslobors.no/message/506937Press contact LifecareChristian SaureChairman of the Boardchristian@sternacap.no+47 909 33 148